Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 - Clinical Trial Not Allowed) expires 10/12/2023
Due Dates: October 11, 2023
Open Date: Earliest Submission Date: September 11, 2023
The purpose of this Notice of Funding Opportunity (NOFO) is to support mechanistic studies of the early stage of Mycobacterium tuberculosis (Mtb) infection, with and without HIV, to identify interventional targets for vaccine and host-directed therapies. This Notice of Funding Opportunity (NOFO) will support mechanistic studies of early Mtb infection (defined as the time between Mtb exposure and early-stage granuloma formation) in the airway and lung with the ultimate goal of understanding these events in the setting of HIV co-infection.
More information here
International Research in Infectious Diseases, including AIDS (R01), expires: 08/20/2022
Application Due Date(s): July 15, 2020; July 15, 2021; July 15 2022, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s): August 19, 2020; August 19, 2021; August 19, 2022, by 5:00 PM local time of applicant organization.
This Funding Opportunity Announcement (FOA) encourages applications from organizations/institutions in eligible foreign countries that propose research related to infectious diseases that are of interest/importance to that country.
https://grants.nih.gov/grants/guide/pa-files/PAR-20-108.html
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01/R21), expires 01/08/2022
Due Dates: January 8, 2020; January 8, 2021; January 10, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.
R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-357.html
R21: https://grants.nih.gov/grants/guide/pa-files/par-19-364.html
Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01/R21 Clinical Trial Not Allowed), expires: 05/08/2021
Application Due Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.
Dissemination and Implementation Research in Health (R01/R21 Clinical Trial Optional), expires: 05/08/2022
Application Due Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
This Funding Opportunity Announcement (FOA) encourages investigators to submit research grant applications that will identify, develop, test, evaluate and/or refine strategies to disseminate and implement evidence-based practices (e.g. behavioral interventions; prevention, early detection, diagnostic, treatment and disease management interventions; quality improvement programs) into public health, clinical practice, and community settings. In addition, studies to advance dissemination and implementation research methods and measures are encouraged.
R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-274.html
R21: https://grants.nih.gov/grants/guide/pa-files/par-19-275.html
R03: https://grants.nih.gov/grants/guide/pa-files/par-19-276.html
Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 and R21), expires: 01/14/2022
R01 Application Due Date(s): January 14, 2020, January 14, 2021, and January 14, 2022 by 5:00 PM local time of applicant organization.
R21 Application Due Date(s): January 14, 2020; January 14, 2021, by 5:00 PM local time of applicant organization
This Funding Opportunity Announcement (FOA) encourages innovative, high risk, high impact research to investigate the innate and/or adaptive immune responses induced by mycobacterial infections, Bacillus Calmette-Guérin vaccine (BCG) and/or candidate Mycobacterium tuberculosis (Mtb) vaccines in HIV-infected or uninfected individuals. Studies that will provide insights into the immune mechanisms required for protection from Mtb infection/re-infection or progression to active disease in latently infected individuals are encouraged. This research is expected to provide data to advance new hypotheses on immune mechanisms that contribute to the advancement of new tuberculosis (TB) vaccines, including in populations also infected with HIV.
R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-307.html
R21: https://grants.nih.gov/grants/guide/pa-files/PAR-18-923.html
Research on the Health of Transgender and Gender Nonconforming Populations (R01/R21), expires 01/08/2021
Application Due Dates: Standard dates/ AIDS dates apply, by 5:00 PM local time of applicant organization.
This funding opportunity announcement (FOA) calls for research on the health of transgender and gender nonconforming people of all ages, including both youth and adults who are questioning their gender identity and those individuals who are making or who have made a transition from being identified as one gender to the other. This group encompasses individuals whose gender identity differs from the sex on their original birth certificate or whose gender expression varies significantly from what is traditionally associated with or typical for that sex.
R01: https://grants.nih.gov/grants/guide/pa-files/PA-18-729.html
R21: https://grants.nih.gov/grants/guide/pa-files/PA-18-728.html